Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

682
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
682
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

419
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

538
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
538
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

6.4K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
6.4K
Aromatic Hydrocarbon Cations: Structural Overview01:18

Aromatic Hydrocarbon Cations: Structural Overview

3.6K
Cycloheptatriene is a neutral monocyclic unsaturated hydrocarbon that consists of an odd number of carbon atoms and an intervening sp3 carbon in the ring. The three double bonds in the ring correspond to 6 π electrons, which is a Huckel number, and therefore satisfies the criteria of 4n + 2 π electrons. However, the intervening sp3 carbon disrupts the continuous overlap of p orbitals. As a result, cycloheptatriene is not aromatic.
Removing one hydrogen from the intervening CH2 group...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Point-of-Care Ultrasound Abnormalities and Raised Serum NT-proBNP in Early-Onset Preeclampsia.

Anesthesia and analgesia·2025
Same author

Kisspeptin signalling and its correlation with placental ultrastructure and clinical outcomes in pregnant South African women with obesity and gestational diabetes.

Placenta·2024
Same author

Cardiometabolic Health in Pregnancy and Postpartum: Findings From a Prospective Cohort Study in South Africa.

Open forum infectious diseases·2024
Same author

Associations of HIV and antiretroviral therapy with gestational diabetes in South Africa.

AIDS (London, England)·2023
Same author

The FIGO Ovulatory Disorders Classification System.

Fertility and sterility·2022
Same author

The FIGO ovulatory disorders classification system.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2022

Related Experiment Video

Updated: Jan 10, 2026

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

11.8K

Cyproterone acetate for hirsutism.

Mushi J Matjila1, Paul Andre Le Roux2, Zephne M van der Spuy1

  • 1Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa.

The Cochrane Database of Systematic Reviews
|November 25, 2025
PubMed
Summary

Cyproterone acetate (CPA) with ethinylestradiol is a common treatment for hirsutism, but evidence suggests limited differences in effectiveness compared to other medications like spironolactone or finasteride. More research is needed to compare the safety and efficacy of various hirsutism treatments.

More Related Videos

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.5K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.4K

Related Experiment Videos

Last Updated: Jan 10, 2026

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

11.8K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.5K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.4K

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Hirsutism, a common endocrine issue causing excessive hair growth in women, is often managed with cyproterone acetate (CPA) and ethinylestradiol.
  • This review is an update of previous research on CPA for hirsutism, first published in 2003.

Purpose of the Study:

  • To evaluate the benefits and harms of cyproterone acetate (CPA), alone or with ethinylestradiol, for treating hirsutism.
  • To compare CPA's effectiveness against other medications in reducing hair growth and improving endocrine profiles in women with hirsutism.

Main Methods:

  • Conducted a systematic search of multiple databases for randomized controlled trials (RCTs) up to December 2022.
  • Included RCTs involving women of reproductive age with idiopathic hirsutism or hirsutism secondary to ovarian hyperandrogenism (Ferriman Gallwey score > 7).
  • Analyzed primary outcomes such as clinical parameters (FG scores, hair growth) and secondary outcomes including endocrine markers and side effects.

Main Results:

  • Limited differences were found in hirsutism scores (FG) and free testosterone levels when comparing different doses of CPA with ethinylestradiol.
  • Cyproterone acetate (CPA) plus ethinylestradiol showed comparable efficacy to finasteride, spironolactone, and ketoconazole in reducing hirsutism, with some evidence suggesting slight advantages over flutamide.
  • Evidence suggests CPA plus ethinylestradiol may offer little to no difference in efficacy compared to finasteride or spironolactone when combined with ethinylestradiol, though some comparisons showed uncertainty.

Conclusions:

  • While some differences in clinical outcomes were observed between CPA and specific agents like spironolactone and finasteride, overall clinical differences were not significant across many comparisons.
  • Small study sizes and inconsistent assessment methods limit definitive conclusions on the comparative efficacy and safety of various hirsutism treatments.
  • Larger, well-designed studies are necessary to thoroughly compare the efficacy and safety profiles of available therapeutic options for hirsutism.